353 related articles for article (PubMed ID: 14529478)
21. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
Kim DH; Kim M; Kwon HJ
J Biochem Mol Biol; 2003 Jan; 36(1):110-9. PubMed ID: 12542981
[TBL] [Abstract][Full Text] [Related]
22. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents.
Jones P; Steinkühler C
Curr Pharm Des; 2008; 14(6):545-61. PubMed ID: 18336299
[TBL] [Abstract][Full Text] [Related]
23. [Histone-deacetylases inhibitors: from TSA to SAHA].
Peixoto P; Lansiaux A
Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors: anticancer compounds.
Smith KT; Workman JL
Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
[TBL] [Abstract][Full Text] [Related]
25. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
26. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
27. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
28. Chemical origins of isoform selectivity in histone deacetylase inhibitors.
Butler KV; Kozikowski AP
Curr Pharm Des; 2008; 14(6):505-28. PubMed ID: 18336297
[TBL] [Abstract][Full Text] [Related]
29. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylases: unique players in shaping the epigenetic histone code.
Thiagalingam S; Cheng KH; Lee HJ; Mineva N; Thiagalingam A; Ponte JF
Ann N Y Acad Sci; 2003 Mar; 983():84-100. PubMed ID: 12724214
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors open new doors in cancer therapy.
McLaughlin F; La Thangue NB
Biochem Pharmacol; 2004 Sep; 68(6):1139-44. PubMed ID: 15313411
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Shankar S; Srivastava RK
Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
[TBL] [Abstract][Full Text] [Related]
33. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
34. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors and anticancer therapy.
Kouraklis G; Theocharis S
Curr Med Chem Anticancer Agents; 2002 Jul; 2(4):477-84. PubMed ID: 12678732
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
38. Targeted histone deacetylase inhibition for cancer therapy.
Vigushin DM; Coombes RC
Curr Cancer Drug Targets; 2004 Mar; 4(2):205-18. PubMed ID: 15032670
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
Fang JY
J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
[TBL] [Abstract][Full Text] [Related]
40. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
